Anika Therapeuticsreported 4Q19 orthopedic revenue of USD $26 million, +9.5% vs. 4Q18, with full-year 2019 revenue of $101 million, +8% vs. 2018. The company made significant progress in 2019 on its transformation to a global commercial organization. Anika launched its first surgical orthopedic product, TACTOSET, in December 2019 and expects approximately $3 million in revenue from the product in 2020. The company followed that launch with its January 2020 acquisition of Parcus Medical and Arthrosurface that significantly expand both its portfolio and access to operating rooms. Anika’s CINGAL next-generation osteoarthritis product grew close to 30% in 2019 and the company is working diligently for FDA approval. Domestically, fourth-quarter volume and average selling price for the company’s ORTHOVISC and MONOVISC
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
4Q19
4Q18
$ Chg
% Chg
Orthobiologics
$26.0
$23.8
$2.2
9.5%
FY 19
FY 18
$ Chg
% Chg
Orthobiologics
$101.0
$93.6
$7.4
8%
Geographic Sales
Region
4Q19
4Q18
$ Chg
% Chg
US
$20.8
$19.5
$1.3
6.8%
Ex-US
$5.2
$4.3
$0.9
21.6%
Europe
$2.9
$2.4
$0.5
20.4%
Other
$2.3
$1.9
$0.4
23.1%
Grand Total
$26.0
$23.8
$2.2
9.5%
Earnings
Amt
% of Sales
Sales
$29.8
Cost of Sales
($8.6)
29.1%
R & D
($4.1)
13.7%
Selling and Admin
($12.2)
41.1%
Other
($0.7)
2.5%
Net Earnings
$4.1
13.6%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Anika Therapeuticsreported 4Q19 orthopedic revenue of USD $26 million, +9.5% vs. 4Q18, with full-year 2019 revenue of $101 million, +8% vs. 2018. The company made significant progress in 2019 on its transformation to a global commercial organization. Anika launched its first surgical orthopedic product, TACTOSET, in December 2019 and...
Anika Therapeuticsreported 4Q19 orthopedic revenue of USD $26 million, +9.5% vs. 4Q18, with full-year 2019 revenue of $101 million, +8% vs. 2018. The company made significant progress in 2019 on its transformation to a global commercial organization. Anika launched its first surgical orthopedic product, TACTOSET, in December 2019 and expects approximately $3 million in revenue from the product in 2020. The company followed that launch with its January 2020 acquisition of Parcus Medical and Arthrosurface that significantly expand both its portfolio and access to operating rooms. Anika’s CINGAL next-generation osteoarthritis product grew close to 30% in 2019 and the company is working diligently for FDA approval. Domestically, fourth-quarter volume and average selling price for the company’s ORTHOVISC and MONOVISC
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
4Q19
4Q18
$ Chg
% Chg
Orthobiologics
$26.0
$23.8
$2.2
9.5%
FY 19
FY 18
$ Chg
% Chg
Orthobiologics
$101.0
$93.6
$7.4
8%
Geographic Sales
Region
4Q19
4Q18
$ Chg
% Chg
US
$20.8
$19.5
$1.3
6.8%
Ex-US
$5.2
$4.3
$0.9
21.6%
Europe
$2.9
$2.4
$0.5
20.4%
Other
$2.3
$1.9
$0.4
23.1%
Grand Total
$26.0
$23.8
$2.2
9.5%
Earnings
Amt
% of Sales
Sales
$29.8
Cost of Sales
($8.6)
29.1%
R & D
($4.1)
13.7%
Selling and Admin
($12.2)
41.1%
Other
($0.7)
2.5%
Net Earnings
$4.1
13.6%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
